A Non Randomized, Open Label, Phase II Trial to Assess the Efficacy and Safety of Bevacizumab Plus Capecitabine and Oxaliplatin, as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polichemotherapy Treatment.

Trial Profile

A Non Randomized, Open Label, Phase II Trial to Assess the Efficacy and Safety of Bevacizumab Plus Capecitabine and Oxaliplatin, as First Line Treatment for Elderly Patients With Metastatic Colorectal Adenocarcinoma, Suitable for Polichemotherapy Treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Acronyms BECOX
  • Most Recent Events

    • 19 Jun 2014 Status changed from active, no longer recruiting to completed according to results published in the British Journal of Cancer.
    • 29 Jan 2014 Planned End Date changed from 1 Dec 2012 to 1 Mar 2014 as per ClinicalTrials.gov record.
    • 20 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top